Eli Lilly and Company, Johnson & Johnson, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, or sell prescription and other medicines. For investors, their value can be affected by drug approvals, patent expirations, clinical-trial results, competition, and healthcare regulations. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of LLY traded up $7.42 during midday trading on Friday, hitting $1,372.15. The stock had a trading volume of 3,802,992 shares, compared to its average volume of 2,816,128. The stock's 50 day moving average is $1,215.24 and its 200 day moving average is $1,101.16. The firm has a market cap of $1.29 trillion, a PE ratio of 44.54, a price-to-earnings-growth ratio of 1.69 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,453.00.
Read Our Latest Research Report on LLY
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of JNJ stock traded up $3.82 during trading hours on Friday, reaching $276.14. 8,859,790 shares of the stock were exchanged, compared to its average volume of 7,963,982. The firm has a market capitalization of $664.76 billion, a price-to-earnings ratio of 41.84, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22. Johnson & Johnson has a 12-month low of $185.12 and a 12-month high of $282.02. The company's 50-day moving average price is $265.91 and its 200-day moving average price is $248.30. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.
Read Our Latest Research Report on JNJ
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
AbbVie stock traded up $3.27 during midday trading on Friday, reaching $291.51. The stock had a trading volume of 5,039,501 shares, compared to its average volume of 5,631,433. AbbVie has a 52-week low of $190.75 and a 52-week high of $302.93. The firm has a market cap of $515.27 billion, a price-to-earnings ratio of 50.17, a price-to-earnings-growth ratio of 1.32 and a beta of 0.20. The company has a fifty day moving average of $271.98 and a 200 day moving average of $239.04.
Read Our Latest Research Report on ABBV
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
